Discover
IBIO
iBio, Inc.
1.75
2 x 1.51
2 x 2.22
bid
ask
+
0.00
0.00%
2 @ 05:41 AM
1.79 +0.04 (2.29%)
| Ytd | -9.33% | |
| 1y | 133.33% |
1.71
day range
2.11
0.56
52 week range
3.82
| Open | 1.76 | Prev Close | 1.75 | Low | 1.71 | High | 2.11 | Mkt Cap | 86.94M |
| Vol | 5.04M | Avg Vol | 924.81K | EPS | -0.56 | P/E | N/A | Forward P/E | -1.44 |
| Beta | -3.37 | Short Ratio | 1.92 | Inst. Own | 31.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-22 | 50-d Avg | 1.71 | 200-d Avg | 1.76 | 1yr Est | 3.60 |
IBIO News
benzinga.com
iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporti
globenewswire.com
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eigh
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporti
benzinga.com
Raymond James Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5
Raymond James analyst Martin Auster initiates coverage on iBio (NASDAQ:IBIO) with a Outperform ra
benzinga.com
iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinic
iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innov